8 completed, 2 active not recruiting, 2 recruiting, 1 not yet recruiting. 5 Phase 1, 2 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 5 | Completed 3, Active not recruiting 1, Recruiting 1 |
| Phase 2 | 2 | Completed 2 |
Follow Renal Pelvis Cancer: new trials by email Literature Review of Renal Pelvis Cancer trials Research Report on Renal Pelvis Cancer
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Performance Evaluation of Urine DNA Methylation Testing for the Detection of Urothelial Carcinoma in Patients With Hematuria Hematuria, Urothelial Carcinoma | Not yet recruiting | Changhai Hospital | 1200 | 2024-07-01 | 2024-07-05 | |
| A Study of LY4052031 in Participants With Advanced or Metastatic Urothelial Cancer or Other Solid Tumors LY4052031, Pembrolizumab - Metastatic Solid Tumor, Recurrent Solid Tumor | Phase 1 | Recruiting | Eli Lilly and Company | 460 | 2024-07-01 | 2026-11-04 |
| Urine DNA Methylation Detection for Hematuria Evaluation Hematuria, Urothelial Carcinoma | Unknown | Changhai Hospital | 71 | 2024-06-15 | 2024-06-20 | |
| A Study of LY4101174 in Participants With Recurrent, Advanced or Metastatic Solid Tumors LY4101174 - Metastatic Solid Tumor, Recurrent Solid Tumor | Phase 1 | Active not recruiting | Eli Lilly and Company | 490 | 2024-03-05 | 2026-05-22 |
| Radical Radiotherapy Versus Radical Surgery for UTUC Radical nephroureterectomy, Radical radiotherapy - Renal Pelvis Cancer | Recruiting | Peking University First Hospital | 60 | 2022-01-01 | 2024-10-22 | |
| Blood Sample Collection to Evaluate Biomarkers in Subjects With Untreated Solid Tumors Blood Sample Collection - Breast Cancer, Lung Cancer | Completed | Exact Sciences Corporation | 5133 | 2018-08-23 | 2022-09-01 | |
| Enzalutamide in Combination With Gemcitabine and Cisplatin in Bladder Cancer Enzalutamide, Cisplatin, Gemcitabine - Bladder Cancer, Carcinoma, Transitional Cell | Phase 1 | Completed | H. Lee Moffitt Cancer Center and Research Institute | 10 | 2015-02-11 | 2019-08-01 |
| A Trial With Vinflunine in Patients With Metastatic Bladder Cancer and Impaired Renal Function Vinflunine, Gemcitabine, Carboplatin - Urothelial Carcinoma, Bladder Cancer | Phase 2 | Completed | Dr Anders Ullén | 62 | 2014-04-01 | 2019-10-08 |
| Phase I Study With Sorafenib in Addition to Vinflunine in Metastatic Transitional Cell Carcinoma of the Urothelial Tract Vinflunine, Sorafenib - Urothelial Carcinoma, Bladder Cancer | Phase 1 | Completed | Dr Anders Ullén | 22 | 2012-05-01 | 2019-04-26 |
| Gemcitabine and Split-Dose Cisplatin Plus Everolimus (RAD001) in Patients With Advanced Solid Tumor Malignancies gemcitabine and split-dose cisplatin plus escalating doses of continuous Everolimus (RAD001) - Bladder Cancer, Renal Pelvis Cancer | Phase 1 | Completed | Memorial Sloan Kettering Cancer Center | 12 | 2010-08-01 | 2016-03-31 |
| Cancer in Patients With Gabapentin (GPRD) Gabapentin prescriptions - Pain, Neuropathic, Epilepsy | Completed | GlaxoSmithKline | 2323608 | 2010-06-01 | 2017-07-06 | |
| Gabapentin and Risk of Pancreatic Cancer and Renal Cancer (GPRD) Gabapentin prescriptions - Renal Pelvis Cancer, Restless Legs Syndrome | Completed | GlaxoSmithKline | 54202 | 2010-03-01 | 2017-05-30 | |
| A Genotype-Phenotype Urothelial Cancer Registry saliva sample and questionaire, saliva sample, questionaire - Urothelial Cancer, Renal Pelvis Cancer | Active not recruiting | Memorial Sloan Kettering Cancer Center | 3519 | 2009-05-01 | 2026-08-24 | |
| A Phase II Study of AZD4877 (a Novel Anti-mitotic Agent) in Advanced Bladder Cancer AZD4877 - Bladder Cancer, Transitional Cell Bladder Cancer | Phase 2 | Completed | AstraZeneca | 54 | 2008-05-01 | 2011-01-12 |
Urinary Bladder Neoplasms (12) · Ureteral Neoplasms (10) · Carcinoma, Transitional Cell (5) · Pancreatic Neoplasms (5) · Urethral Neoplasms (4) · Esophageal Neoplasms (3) · Kidney Neoplasms (3) · Ovarian Neoplasms (3) · Prostatic Neoplasms (3) · Breast Neoplasms (2) · Carcinoma, Non-Small-Cell Lung (2) · Carcinoma, Renal Cell (2) · Diabetes Mellitus (2) · Epilepsy (2) · Hematuria (2)
Female Urogenital Diseases (13) · Female Urogenital Diseases and Pregnancy Complications (13) · Male Urogenital Diseases (13) · Neoplasms by Site (13) · Urogenital Diseases (13) · Urogenital Neoplasms (13) · Urologic Diseases (13) · Neoplasms (12) · Urinary Bladder Diseases (11) · Urologic Neoplasms (11) · Neoplasms by Histologic Type (9) · Neoplasms, Glandular and Epithelial (9) · Ureteral Diseases (9) · Carcinoma (8) · Pathologic Processes (7)
Gemcitabine (3) · vinflunine (2) · Carboplatin (1) · Cisplatin (1) · Everolimus (1) · N-(3-aminopropyl)-N-(1-(5-benzyl-3-methyl-4-oxo-(1,2)thiazolo(5,4-d)pyrimidin-6-yl)-2-methylpropyl)-4-methylbenzamide (1) · Sorafenib (1) · enzalutamide (1) · pembrolizumab (1)
Changhai Hospital (2) · Dr Anders Ullén (2) · Eli Lilly and Company (2) · GlaxoSmithKline (2) · Memorial Sloan Kettering Cancer Center (2) · AstraZeneca (1) · Exact Sciences Corporation (1) · H. Lee Moffitt Cancer Center and Research Institute (1) · Peking University First Hospital (1)
United States (7) · China (5) · Spain (3) · Australia (2) · Denmark (2) · France (2) · Japan (2) · Sweden (2) · United Kingdom (2) · Belgium (1) · Canada (1) · Germany (1) · South Korea (1)
Dean Bajorin, MD (1) · Gary Hudes, MD (1) · Iyer Gopakumar, MD (1) · Jingsong Zhang, M.D., Ph.D. (1) · Shilpa Gupta, M.D. (1)
PMID 23329066, PMID 30552156, PMID 31648851
2023 (1)